Overview

This course focuses on health care organizations’ financial decisions in the changing health care landscape. The course involves case analyses and lectures, including presentations by practitioners with extensive real world experience. Upon completion of the course, students will be able to utilize a range of financial tools and techniques for making value-added financial decisions in numerous health care contexts.

The course is organized around cases dealing with valuation and return on investment of biopharmaceutical and medical technology development projects, valuation of publicly-traded health care companies, valuation and deal structure for startup and early stage health care organizations, health plan pricing and finance, and health care provider risk-sharing arrangements. Each case is accompanied by background on tools, methods, institutions, and markets.

Students seeking careers in health care with minimal finance background will obtain a solid introduction to key areas of health care finance and financial decision making. Students with more background will broaden and enhance their analytical and interpretive skills in a variety of important applications.

Prerequisites: FNCE 611, equivalent coursework, or experience

Canvas site: The cases and readings not accessible by direct links will be posted on the course Canvas site. Some speakers may provide additional readings. A copy of the lecture slides usually will be distributed in class and posted after class.

Guest speakers

- Geoff Meyerson, Managing Director and Co-founder, Locust Walk Partners
- Adam Koppel, Managing Director, Bain Capital
- Richard Evans, Healthcare practice leader, SSR
- Michael Aberman, Senior Vice President of Strategy and Investor Relations, and Nouhad Husseini, Senior Director of Business Development, Regeneron Pharmaceuticals
- Robert Seltzer, Managing Partner, Amzak Health, Majalin LLC
- Maureen Spivack, Managing Director, Healthcare investment banking team, KPMG
- Robert Broermann, Senior Vice President and Chief Financial Officer, Sentara Healthcare
- Carolyn Magill, CEO, Remedy Partners
Case teams, write-ups, and presentation

Groups of up to three-four students should assemble to form a case team. Each team will be responsible for submitting 4 case write-ups and presenting one case in class. A case write-up should consist of no more than 6 pages of text, with as many supporting exhibits and figures as needed. More details on content and format will be provided in class.

A team’s oral presentation should take approximately 15-20 minutes, with each member required to participate. The presenting team should turn in its slides/overheads and may also turn in a write-up if the presentation slides do not fully reflect the team’s analysis.

A team member’s overall case grade may be adjusted based on teammate evaluations.

Exam

An exam will be given in class on November 21. All course material is eligible, including presentations by guest speakers. You can bring one sheet of paper with helps on one side. If essential, a makeup exam will be given at the final examination time for MW classes beginning at 1:30.

Course grade

<table>
<thead>
<tr>
<th></th>
<th>Numerical Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case write-ups</td>
<td>40%</td>
</tr>
<tr>
<td>Case presentation</td>
<td>15%</td>
</tr>
<tr>
<td>Class participation</td>
<td>25%</td>
</tr>
<tr>
<td>Exam (November 21 in class)</td>
<td>20%</td>
</tr>
</tbody>
</table>

Protocol

- Attendance is important, including all case and outside speaker dates. Missing class on those dates will significantly reduce your participation grade.
- No laptops, tablets, smart phones, etc. during class.

Outline

August 31: Introduction and context


September 7 & 12: Basic valuation, valuing drugs in development

- Discounted cash flow valuation basics
- Key features of investment in biotech/pharma/medtech projects
- Development stages and representative cash flows
- Unpacking the average cost of drug development
- Expected net present value of a drug in development


**September 14:** Adding value through partnering
- Licensing basics, economic and financial drivers
- Valuation, incentives, and deal terms
- Pre- and post-deal opportunism and mitigation


**September 19:** Geoff Meyerson, Managing Director and Co-founder, Locust Walk Partners

**September 21:** Case 1 due – ENPV of a drug

**September 26, Adam Koppel,** Managing Director, Bain Capital

**September 28:** Learning and the value of flexibility in development
- Simple and more realistic examples of the value of flexibility
- Using decision tree analysis to value flexibility
- Project discount rates, R&D leverage, and risk
- Simple and fancy ways to model flexibility

“Getting Real about Valuation in Biotech,” *Nature Biotechnology*, April 2005

**October 3 & 5:** Valuing health care companies
- Valuation using comparable firms and transactions
- Discounted value of free cash flows
- Terminal values and their limitations
- Estimating the cost of equity capital for health care companies and whether it matters
- How R&D leverage affects the cost of capital

“Valuation Multiples – A Primer,” UBS Warburg, 2001 (detailed and often technical background, which might be helpful for some)

**October 10, Richard Evans,** Healthcare practice leader, SSR

**October 12:** Case 2 due – Valuing a company with pipeline drugs

**October 17, Michael Aberman and Nouhad Husseini,** Regeneron Pharmaceuticals

**October 19 & 24:** Financing early stage health care companies
- Role and structure of venture capital finance
- Trends in funding and exits by subsector
- Valuation, dividing value, and the “VC” method
- Why VC target returns are often so high
- Deal terms, payoffs, and incentives
Convertible preferred stock and its variants

“Trends in Healthcare Investments and Exits 2016,” Silicon Valley Bank (background)
“RockHealth, Digital Health Funding Mid-Year Review – 2016,”
https://rockhealth.com/reports/digital-health-funding-2016-midyear-review/

October 26: Robert Seltzer, Managing Partner, Amzak Health

October 31: Case 3 due – Deal structure for an early stage health care company

November 2, 7, & 9: Health insurance and managed care

• Background on economics of health insurance and market overview
• Understanding medical loss ratios
• Role and operation of risk adjustment schemes, example of Medicare Advantage
• What’s a risk score, and why it’s important
• Affordable Care Act’s exchanges and subsidies, risk adjustment, reinsurance, risk corridors and effects on employers, insurance offers, and employment

“Risk Adjustment in Health Insurance,” Health Affairs Health Policy Brief, August 2012
“Evolving the Risk-Adjustment Model to Improve Payment Accuracy in the Individual & Small Group Market,” Avalere Health, March 206
“Issues in Risk Adjustment for Medicare Advantage,” MedPac, June 2012 (Case 4 background)
“Improving Risk Adjustment in the Medicare Program, MedPac, June 2014 (Case 4 background)

November 14: Case 4 due – Risk adjustment and plan design

November 16: Maureen Spivack, Managing Director, Healthcare investment banking team, KPMG

November 21: Exam

November 28: Risk sharing and payment design – bundled payments

• Medical care provider reimbursement, risk, and incentives
• Basic economics of bundled payment arrangements
• Medicare and private payer bundled payment initiatives
• Financial risk and its transfer

“Hospital-Physician Gainsharing in Cardiology,” Health Affairs, 2008 (background for Case 5)
“UHC Supply Cost and Quality Analytics,” UHC Intelligence, 2015 (background for Case 5)

**November 30:** Robert Broermann, SVP and CFO, Sentara Healthcare

**December 5:** Payer/provider risk sharing
- From health maintenance organizations to accountable care organizations
- One-sided vs. two-sided sharing models
- Physician risk sharing


**December 7:** Carolyn Magill, CEO, Remedy Partners

**December 12:** Case 5 due – Bundled payments for hospitals and physicians